immune physicians

The archived
replays will be available on the Idenix website for two weeks following the
presentations . The replay can be accessed from this
same website and will be available within 24 hours of the
presentation .

disease california

The webcast will be available for replay beginning
shortly after the completion of the live meeting .
Media: Teri Dahlman (617) 995-9905
Investors: Amy Sullivan (617) 995-9838

conferences faq

D., Idenix's chairman and chief executive officer, will present
a corporate overview at the upcoming Leerink Swann + Company/Medacorp
Inaugural Health Care Conference on Tuesday, March 1, 2005 at 3:00 p.'s 25th
Annual Healthcare Conference. A Market Authorization Application is under review by
the European Medicines Agency for the use of ATryn(R) in patients with
a hereditary antithrombin deficiency .

front pharmacists

DEERFIELD, Ill. CAMBRIDGE, Mass.com.

GTC Biotherapeutics to Webcast Corporate Presentation at SG Cowen + Co.'s 25th Annual Healthcare Conference

faq form

, through its subsidiaries, assists healthcare
professionals and their patients with the treatment of complex medical
conditions, including cancer , hemophilia, immune disorders, kidney disease and
trauma. Idenix's current focus is on the treatment of infections
caused by hepatitis B virus, hepatitis C virus and human immunodeficiency
virus (HIV).D.

nurses orange

com

front deficiency

, Idenix
Pharmaceuticals, Inc.

conditions aids

This event will be webcast and
can be accessed, along with supporting slides, at Baxter's website at
http://www. ET at
the Plaza Hotel , New York and at the Goldman Sachs Small Cap Growth Conference
on Friday, March 11, 2005 at 8:30 a.

conference registration

m. (CST).:
Baxter International Inc.

Contact:
Idenix Pharmaceuticals, Inc .

diseases california

Idenix Pharmaceuticals to Present at the Leerink Swann Inaugural Health Care Conference and the Goldman Sachs Small Cap Growth Conference

The live and archived webcast of both presentations can be accessed under
"Events" in the Idenix Investor Center at http://www.

GTC Biotherapeutics is a leader in the development, production,
and commercialization of therapeutic proteins through transgenic
animal technology.

hiv center

m.----GTC
Biotherapeutics, Inc.

conferences conference

The company applies its expertise in medical devices, pharmaceuticals
and biotechnology to make a meaningful difference in patients ' lives. The conference is being held at the
Boston Marriott Copley Place from March 14 through March 17, 2005.gtc-bio.

update immune

front california

About Baxter International Inc. ET at the 32 Old Slip Conference
Center , New York. Idenix's headquarters are located in Cambridge, Massachusetts
and it has drug discovery operations in Montpellier, France and Cagliari,
Italy. GTC currently has five products in its internal
pipeline and a portfolio of external program production opportunities.

disorders conference

com/ .m.

form diseases

, -- Baxter International
(NYSE: BAX) will host an Investor Conference on Wednesday, May 25, 2005 at The
Ritz-Carlton Chicago , 160 East Pearson Street, Chicago, Illinois., Chairman and CEO of the Company, is scheduled to
present an update on GTC's product and corporate development on
Thursday, March 17, 2005 at 8:00 a.m.
GTC 's lead program is ATryn(R), its recombinant form of human
antithrombin.

california orange

baxter.idenix.

About Idenix:
Idenix Pharmaceuticals, Inc.
The presentation will be webcast live and can be accessed by
logging onto www.

orange nurses

front line

front update

Baxter International Inc. to Host Investor Conference on May 25 2005

("GTC", Nasdaq: GTCB) announced today that
Geoffrey Cox, Ph.

line disease

(Nasdaq: IDIX) announced today that Jean-Pierre
Sommadossi, Ph. during SG Cowen + Co.com. GTC's external program collaborations
are developing transgenically produced versions of products such as
monoclonal antibodies and immunoglobulin fusion proteins for
conditions such as rheumatoid arthritis, HIV/AIDS and cancer.gtc-bio.

registration update

The meeting will begin at 8:00 a.

Biotech Writers
BIOWIRE2K
SG Cowen + Co.'s 25th Annual Healthcare Conference

FRAMINGHAM, Mass.
In its external programs, GTC's technology is used to develop
transgenic production of its partners' proprietary products, including
both large-volume protein therapeutics as well as products that are
difficult to produce in significant quantities from conventional
recombinant production systems.

conditions diseases

One of
the external programs is in clinical trials with a transgenically
produced product.

disease clinical

is a biopharmaceutical company engaged in the
discovery and development of drugs for the treatment of human viral and other
infectious diseases. In addition to the ATryn(R)
program, GTC is developing a recombinant human albumin, a recombinant
human alpha-1 antitrypsin, a malaria vaccine, and a CD137 antibody to
stimulate the immune system as a potential treatment for solid tumors. Additional information is available on the GTC web
site , http://www.